Sep 24 |
Revolution Medicines added to JPMorgan focus list due to NSCLC asset
|
Sep 14 |
Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
|
Sep 9 |
Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels
|
Aug 11 |
Revolution Medicines, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
Aug 11 |
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
|
Aug 9 |
Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
|
Aug 8 |
Q2 2024 Revolution Medicines Inc Earnings Call
|
Aug 7 |
Revolution Medicines GAAP EPS of -$0.81 misses by $0.03
|
Aug 7 |
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
|
Aug 1 |
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
|